Pharma
-
Merck’s $10 Billion Bet On Verona: Smart Strategic Pivot Or Costly Diversion From The Keytruda Cliff?
Merck has made headlines yet again with its $10 billion acquisition of Verona Pharma, a bold move aimed at cushioning…
Read More » -
Eli Lilly’s Obesity Pill Could Be a Game-Changer — But Here’s Why Zepbound Already Has a Giant Lead
Eli Lilly has taken a commanding position in the obesity drug market with its GLP-1 agonist Zepbound, and now the…
Read More » -
Hims & Hers Stock Plunges After Novo Nordisk Breakup: What Really Happened?
Hims & Hers Health saw its stock crash by over 35% in a matter of days after Novo Nordisk announced…
Read More » -
Eli Lilly’s $1.3 Billion Gene Editing Bet: What the Verve Deal Signals for the Future of Heart Disease!
Eli Lilly has expanded into cardiovascular treatment with its $1.3 billion acquisition of Verve Therapeutics, a clinical-stage gene-editing company focused…
Read More » -
ASBP: Unlocking Multi-Billion Dollar Markets with Enhanced Drug Delivery
Enter Aspire Biopharma, Inc. (NASDAQ: ASBP), a pioneering company enhancing existing drugs with their patent-pending, soluble sublingual technology. By delivering…
Read More » -
Aspire Biopharma CEO Interview: Disrupting Drug Delivery with Sublingual Tech
SmallCaps Daily sits down with ASBP’s CEO Kraig Higginson to discuss the company's disruptive technology and the expected clinical and…
Read More » -
NanoViricides Recent Clinical Updates and Milestones Highlight Potential Investor Opportunities
NanoViricides, Inc. (NYSE American: NNVC), a pioneering, clinical-stage biopharmaceutical company, is disrupting the antiviral game with its innovative, first-in-class, nanoviricides®…
Read More » -
Decoded: Why Did Johnson & Johnson Spend $2 billion To Acquire Ambrx Biopharma?
In a groundbreaking move, pharmaceutical giant Johnson & Johnson has set the stage for a significant leap forward in cancer…
Read More » -
TG Therapeutics: Is It Time to Invest In This Biotech Player After The Unprecedented 36.4% Jump?
TG Therapeutics' stock soared an astonishing 36.4% higher in a single session on the heels of the company's impressive third-quarter…
Read More » -
OKYO Pharma: An Emerging Biopharma With Game Changing Treatments In Ophthalmology
OKYO Pharma's main drug has already surpassed Phase 1 and reached Phase 2. OK-101 is catering to niches within the…
Read More »
